On Oct 30, major Wall Street analysts update their ratings for $Sage Therapeutics (SAGE.US)$, with price targets ranging from $4 to $26.
J.P. Morgan analyst Anupam Rama maintains with a hold rating.
TD Cowen analyst Ritu Baral maintains with a hold rating, and maintains the target price at $10.
Mizuho Securities analyst Uy Ear maintains with a hold rating.
Needham analyst Ami Fadia maintains with a hold rating.
RBC Capital analyst Brian Abrahams maintains with a sell rating, and maintains the target price at $4.
Furthermore, according to the comprehensive report, the opinions of $Sage Therapeutics (SAGE.US)$'s main analysts recently are as follows:
Sage Therapeutics has been observed to report third quarter results with notable total revenue, operating expenses, and a cash position that is predicted to extend the company's financial runway into 2026. The disappointing outcome of the SAGE-718 Phase 2 LIGHTWAVE study for patients with Alzheimer's Disease Mild Cognitive Impairment has led to a strategic shift to focus on the development of Zurzuvae and the potential of dalzanemdor for Huntington's Disease Mild Cognitive Impairment, with Phase 2 DIMENSION results anticipated by the end of 2024. Additionally, there is an expectation of relevant updates from Biogen regarding its third quarter in 2024.
Here are the latest investment ratings and price targets for $Sage Therapeutics (SAGE.US)$ from 9 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
